- Home
- GDO vs NRXS Comparison
GDO vs NRXS Comparison
Compare GDO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GDO | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 78.9M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GDO | NRXS |
|---|---|---|
| Price | $10.12 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 50.3K | ★ 83.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $10.14 | $2.21 |
| 52 Week High | $12.15 | $9.33 |
Technical Indicators
Market Signals| Indicator | GDO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 24.96 | 32.39 |
| Support Level | N/A | $5.50 |
| Resistance Level | $10.86 | $7.79 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 3.77 |
Price Performance
Historical ComparisonAbout GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).